A 60-year-old client diagnosed with a new deep vein thrombos… | MyMerci
Medical EmergenciesPA
Question
A 60-year-old client diagnosed with a new deep vein thrombosis is started on enoxaparin therapeutic dose AND warfarin 5 mg orally on the same day. The provider plans transition to oral warfarin only. Which transition criterion should the nurse expect to apply?
1Continue enoxaparin and warfarin together (overlap) for at least 5 days AND until the INR has been within the therapeutic range (typically 2.0-3.0) for at least 24 hours, then discontinue enoxaparin.✓ Correct answer
2Wait to start warfarin until enoxaparin has been given for 5 days first.
3Stop the warfarin and continue enoxaparin only because LMWH is more effective for DVT.
4Stop the enoxaparin tomorrow because warfarin alone is therapeutic by day 2.
Explanation
Warfarin transition rule Warfarin inhibits the synthesis of new vitamin-K-dependent clotting factors (II, VII, IX, X) and proteins C, S. Existing factors must clear before INR rises into therapeutic range — this typically takes 5-7 days. During the warm-up period, the patient is paradoxically pro-thrombotic because protein C (anticoagulant) drops faster than factor II.
Standard transition (CHEST/ACC guideline): • Start warfarin and parenteral anticoagulant (UFH, LMWH, or fondaparinux) on day 1 simultaneously when feasible. • Overlap for at least 5 days AND until INR ≥2.0 for at least 24 hours. • Then stop the parenteral agent and continue warfarin. • Mechanical valves, large clot burden, malignancy may require longer parenteral therapy.
Option 4 (stop tomorrow) leaves the patient unprotected. Option 3 (stop warfarin) defeats the long-term oral plan. Option 2 (delay warfarin) is wrong — warfarin and parenteral start together to overlap.
In-depth explanation
Clinical reasoning summary Warfarin transition rule Warfarin inhibits the synthesis of new vitamin-K-dependent clotting factors (II, VII, IX, X) and proteins C, S. Existing factors must clear before INR rises into therapeutic range — this typically takes 5-7 days. During the warm-up period, the patient is paradoxically pro-thrombotic because protein C (anticoagulant) drops faster than factor II.
Standard transition (CHEST/ACC guideline): • Start warfarin and parenteral anticoagulant (UFH, LMWH, or fondaparinux) on day 1 simultaneously when feasible. • Overlap for at least 5 days AND until INR ≥2.0 for at least 24 hours. • Then stop the parenteral agent and continue warfarin. • Mechanical valves, large clot burden, malignancy may require longer parenteral therapy.
Option 1 (stop tomorrow) leaves the patient unprotected. Option 3 (stop warfarin) defeats the long-term oral plan. Option 4 (delay warfarin) is wrong — warfarin and parenteral start together to overlap.